EUVIMEDEUVIMED entdecken
Crossref

How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?

Reza Yaesoubi

Value in Health · 2024

DOI: 10.1016/j.jval.2024.06.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2024. Verfasst von Reza Yaesoubi. Beteiligte Einrichtung: Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA; Public Health Modeling Unit, Yale School of Public Heal…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Monte Carlo Method. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Probabilistic sensitivity analysis (PSA) is conducted to account for the uncertainty in cost and effect of decision options under consideration. PSA involves obtaining a large sample of input parameter values (N) to estimate the expected cost and effect of each alternative in the presence of parameter uncertainty. When the analysis involves using stochastic models (eg, individual-level models), the model is further replicated P times for each sampled parameter set. We study how N and P should be determined. METHODS: We show that PSA could be structured such that P can be an arbitrary number (say, P=1). To determine N, we derive a formula based on Chebyshev's inequality such that the error in estimating the incremental cost-effectiveness ratio (ICER) of alternatives (or equivalently, the willingness-to-pay value at which the optimal decision option changes) is within a desired level of accuracy. We described 2 methods to confirm, visually and quantitatively, that the N informed by this method results in ICER estimates within the specified level of accuracy. RESULTS: When N is arbitrarily selected, the estimated ICERs could be substantially different from the true ICER (even as P increases), which could lead to misleading conclusions. Using a simple resource allocation model, we demonstrate that the proposed approach can minimize the potential for this error. CONCLUSIONS: The number of parameter samples in probabilistic cost-effectiveness analyses should not be arbitrarily selected. We describe 3 methods to ensure that enough parameter samples are used in probabilistic cost-effectiveness analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisMonte Carlo MethodHumansUncertaintyProbabilityModels, StatisticalStochastic ProcessesModels, Economic

Stichwörter der Autor:innen

Monte Carlocost-effectiveness analysisprobabilistic sensitivity analysissample size

Autor:innen und Institutionen

  • Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA; Public Health Modeling Unit, Yale School of Public Health, New Haven, CT, USA. Electronic address: reza.yaesoubi@yale.edu.

Zitieren

APA

Yaesoubi, R. (2024). How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?. Value in Health. https://doi.org/10.1016/j.jval.2024.06.016

Vancouver

Yaesoubi R. How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?. Value in Health. 2024. doi:10.1016/j.jval.2024.06.016

BibTeX
@article{Yaesoubi2024,
  author = {Yaesoubi, Reza},
  title = {How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?},
  journal = {Value in Health},
  year = {2024},
  doi = {10.1016/j.jval.2024.06.016}
}
Kostenlos starten →